Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer

被引：4
|
作者：
Pujade-Lauraine, Eric [1 ]
机构：
[1] Univ Paris 05, Hop Univ Paris Ctr, Unite Canc Femme & Rech Clin, F-75004 Paris, France
来源：
JOURNAL OF GYNECOLOGIC ONCOLOGY | 2013年 / 24卷 / 03期
关键词：
TRIAL;
D O I：
10.3802/jgo.2013.24.3.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：209 / 211
页数：3
相关论文
共 50 条
  • [41] ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER
    HOSKINS, PJ
    SWENERTON, KD
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 60 - 63
  • [42] Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
    Sostelly, Alexandre
    Mercier, Francois
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [43] Is FDA Approved Bevacizumab Cost-Effective in the Setting of Platinum-Resistant Recurrent Ovarian Cancer?
    Chappell, Nicole P.
    Miller, Caela
    Barnett, Jason
    Fielden, Aaron
    OBSTETRICS AND GYNECOLOGY, 2016, 127 : 6S - 7S
  • [44] Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
    Bamias, A.
    Gibbs, E.
    Lee, C. Khoon
    Davies, L.
    Dimopoulos, M.
    Zagouri, F.
    Veillard, A. -S.
    Kosse, J.
    Santaballa, A.
    Mirza, M. R.
    Tabaro, G.
    Vergote, I.
    Bloemendal, H.
    Lykka, M.
    Floquet, A.
    Gebski, V.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1842 - 1848
  • [45] Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer
    Moffat, Gordon Taylor
    Kong, Weidong
    MacKay, Helen J.
    McGee, Jacob
    Booth, Christopher M.
    Ethier, Josee-Lyne
    GYNECOLOGIC ONCOLOGY, 2024, 184 : 51 - 56
  • [46] Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results
    Czok, S.
    Jewell, A.
    Shawki, S.
    Boyd, L.
    Smith, H.
    Blank, S.
    Muller, C.
    Verschraegen, C.
    Muggia, F.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S83 - S83
  • [47] Multi-Metronomic Bevacizumab Regimens for Resistant Ovarian Cancer
    Bruckner, H. W.
    Hirschfeld, A.
    Stega, J.
    Dottino, P.
    Stega, D.
    Labow, D.
    18TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI), 2014, : 441 - 446
  • [48] Vulnerability of platinum-resistant ovarian cancer to FAK inhibition
    Osterman, Carlos J. Diaz
    Bean, Lisa M.
    Sulzmaier, Florian J.
    Taylor, Kristin N.
    Jiang, Shulin A.
    Tancioni, Isabelle
    Anderson, Kristen
    Jean, Christine
    Chen, Xiao Lei
    Kleinschmidt, Elizabeth G.
    Kolev, Vihren N.
    Weaver, David T.
    Pachter, Jonathan A.
    Connolly, Denise C.
    Molinolo, Alfredo
    Schlaepfer, David D.
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Investigational agents against platinum-resistant ovarian cancer
    Lorusso, Domenica
    Ferrandina, Gabriella
    Fanfani, Francesco
    Gagliardi, Maria Lucia
    Scambia, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (03) : 325 - 336
  • [50] The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer
    Levy, Arkene
    Leynes, Carolina
    Baig, Mirza
    Chew, Sue Anne
    CHEMMEDCHEM, 2019, 14 (21) : 1810 - 1827
12345